Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss
Longevity startup Life Biosciences has begun human clinical trials for its ER-100 drug, which aims to reverse age-related vision loss by rejuvenating optic nerve cells. This marks the first time cellular rejuvenation technology has received FDA clearance for human testing.
Why it matters
If successful, this therapy could validate the epigenetic theory of aging and provide a breakthrough treatment for previously irreversible age-related diseases.
Photo-Illustration: WIRED Staff; Getty Images Comment Loader Save Story Save this story Comment Loader Save Story Save this story A longevity startup has dosed its first patient with a drug to reverse age-related sight loss.
The article reports on a specific medical milestone using neutral, factual language without political or ideological framing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in